Analyst Price Targets — PTC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 30, 2026 11:24 am | — | Stifel Nicolaus | $165.00 | $132.46 | TheFly | PTC price target lowered to $165 from $180 at Stifel |
| July 30, 2026 10:42 am | — | Piper Sandler | $157.00 | $132.46 | TheFly | PTC price target lowered to $157 from $175 at Piper Sandler |
| July 30, 2026 9:17 am | Saket Kalia | Barclays | $155.00 | $132.46 | TheFly | PTC price target raised to $155 from $150 at Barclays |
| July 30, 2026 9:12 am | Daniel Jester | BMO Capital | $164.00 | $132.46 | StreetInsider | PTC Inc. (PTC) PT Raised to $164 at BMO Capital |
| July 24, 2026 12:13 pm | — | BMO Capital | $155.00 | $115.56 | TheFly | PTC price target lowered to $155 from $170 at BMO Capital |
| July 13, 2026 10:26 am | — | Barclays | $150.00 | $124.74 | TheFly | PTC price target lowered to $150 from $185 at Barclays |
| June 18, 2026 11:26 am | — | BNP Paribas | $130.00 | $116.94 | TheFly | PTC initiated with a Neutral at BNP Paribas |
| May 27, 2026 8:22 am | — | Berenberg Bank | $170.00 | $144.88 | TheFly | PTC price target lowered to $170 from $192 at Berenberg |
| May 7, 2026 11:39 am | — | Robert W. Baird | $198.00 | $136.77 | TheFly | PTC price target raised to $198 from $194 at Baird |
| May 7, 2026 9:37 am | — | Barclays | $185.00 | $136.77 | TheFly | PTC price target raised to $185 from $180 at Barclays |
Latest News for PTC
PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?
WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Wells Fargo 21st Annual Healthcare Conference Thursday, Sept.
– 17 abstracts and presentations planned at SSIEM Symposium – – Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – – Continued evidence of meaningful benefit across all patient subgroups – WARREN, N.J., Aug. 24, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that multiple Sephience™ (sepiapterin) scientific…
PTC Therapeutics offers a compelling risk-reward profile, with its valuation not fully reflecting the upside from Sephience and potential ST-920 approval. Sephience, PTCT's lead asset, has driven rapid revenue growth, accounting for 63% of product revenue and expanding across major global markets. ST-920, acquired from Sangamo, is a late-stage gene therapy for Fabry Disease; FDA approval could significantly enhance…
PTC Therapeutics NASDAQ: PTCT plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portfolio while using its existing global commercial and regulatory infrastructure.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.